- Home
- ABSI vs CMPS Comparison
ABSI vs CMPS Comparison
Compare ABSI & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- CMPS
- Stock Information
- Founded
- ABSI 2011
- CMPS 2020
- Country
- ABSI United States
- CMPS United Kingdom
- Employees
- ABSI N/A
- CMPS N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- CMPS Health Care
- Exchange
- ABSI Nasdaq
- CMPS Nasdaq
- Market Cap
- ABSI 338.0M
- CMPS 364.9M
- IPO Year
- ABSI 2021
- CMPS 2020
- Fundamental
- Price
- ABSI $2.79
- CMPS $4.59
- Analyst Decision
- ABSI Strong Buy
- CMPS Strong Buy
- Analyst Count
- ABSI 5
- CMPS 7
- Target Price
- ABSI $8.40
- CMPS $18.83
- AVG Volume (30 Days)
- ABSI 2.9M
- CMPS 1.7M
- Earning Date
- ABSI 08-13-2025
- CMPS 07-31-2025
- Dividend Yield
- ABSI N/A
- CMPS N/A
- EPS Growth
- ABSI N/A
- CMPS N/A
- EPS
- ABSI N/A
- CMPS N/A
- Revenue
- ABSI $4,815,000.00
- CMPS N/A
- Revenue This Year
- ABSI $81.76
- CMPS N/A
- Revenue Next Year
- ABSI $287.79
- CMPS N/A
- P/E Ratio
- ABSI N/A
- CMPS N/A
- Revenue Growth
- ABSI N/A
- CMPS N/A
- 52 Week Low
- ABSI $2.01
- CMPS $2.49
- 52 Week High
- ABSI $6.33
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- ABSI 47.46
- CMPS 59.49
- Support Level
- ABSI $2.65
- CMPS $4.33
- Resistance Level
- ABSI $2.87
- CMPS $5.15
- Average True Range (ATR)
- ABSI 0.19
- CMPS 0.38
- MACD
- ABSI -0.01
- CMPS -0.01
- Stochastic Oscillator
- ABSI 24.03
- CMPS 66.65
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.